Blonanserin
As of the edition of 20 October 2026, Blonanserin is a small molecule: marketed, first approved in 2008 (JP); acts on DRD2, DRD3 and HTR2A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Lonasen
- First approved
- 25 January 2008 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Sumitomo Dainippon Pharma Co., Ltd.; 2 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Blonanserin.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Dainippon Sumitomo Pharma | Originator | 2008 to now |